Approximately 15 percent of those with a COVID-19 infection will develop long COVID. Long COVID is prevalent and more common among females and older individuals.
This is a series on the advances in CAR T, a remarkable immunotherapy treatment dubbed a “living drug.” This new therapy genetically modifies a patient’s cells to fight cancer, but current research efforts hope to treat autoimmune diseases, organ damage and more.